Literature DB >> 23788509

Usefulness of allogeneic hematopoietic stem cell transplantation in first complete remission for pediatric blastic plasmacytoid dendritic cell neoplasm with skin involvement: a case report and review of literature.

Kazuo Sakashita1, Shoji Saito, Ryu Yanagisawa, Miyuki Tanaka, Kentaro Yoshikawa, Koichi Hirabayashi, Keiko Tsukahara, Mitsuo Motobayashi, Yozo Nakazawa, Kenichi Koike.   

Abstract

No standard treatment has been established in childhood blastic plasmacytoid dendritic cell neoplasma (BPDCN) because of its rarity. We treated with acute lymphoblastic leukemia-type regimen for a child with BPDCN with skin and leukemic involvement. She has been disease-free for 4 years after allogeneic bone marrow transplantation in first complete remission. In 33 cases of pediatric BPDCN, the over survival was significantly lower in the patients with skin manifestation than those without cutaneous involvement. Accordingly, it is important to determine whether allogeneic hematopoietic stem cell transplantation should be applied to first complete remission in the patients with poor prognosis.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  blastic plasmacytoid dendritic cell neoplasm; bone marrow transplantation; childhood; skin involvement

Mesh:

Year:  2013        PMID: 23788509     DOI: 10.1002/pbc.24622

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  5 in total

1.  Effective Treatment of a Childhood Blastic Plasmacytoid Dendritic Cell Neoplasm with a Cutaneous Tumor Alone by Stem Cell Transplantation with Reduced Intensity Conditioning.

Authors:  Maiko Shimomura; Takaki Asano; Aya Furue; Mizuka Miki; Yasuhiko Sera; Hiroshi Kawaguchi; Kazuhiro Nakamura; Masao Kobayashi
Journal:  Indian J Hematol Blood Transfus       Date:  2015-04-21       Impact factor: 0.900

2.  In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.

Authors:  Fanny Angelot-Delettre; Anne Roggy; Arthur E Frankel; Baptiste Lamarthee; Estelle Seilles; Sabeha Biichle; Bernard Royer; Eric Deconinck; Eric K Rowinsky; Christopher Brooks; Valerie Bardet; Blandine Benet; Hind Bennani; Zehaira Benseddik; Agathe Debliquis; Daniel Lusina; Mikael Roussel; Françoise Solly; Michel Ticchioni; Philippe Saas; Francine Garnache-Ottou
Journal:  Haematologica       Date:  2014-11-07       Impact factor: 9.941

3.  Reduced intensity allogeneic stem cell transplant for treatment of blastic plasmacytoid dendritic cell neoplasm.

Authors:  Anand Lokare; Emmanouil Nikolousis; Neil Phillips; Zbigniew Rudzki; Richard Lovell; Bhuvan Kishore; Don Milligan; Shankara Paneesha
Journal:  Hematol Rep       Date:  2014-01-29

Review 4.  Blastic Plasmacytoid Dendritic Cell Neoplasm in the Pediatric Population: A Case Series and Review of the Literature.

Authors:  Catherine M Nguyen; Lauren Stuart; Hadas Skupsky; Yun-Sun Lee; Arline Tsuchiya; David S Cassarino
Journal:  Am J Dermatopathol       Date:  2015-12       Impact factor: 1.533

5.  Improved in vitro and in vivo activity against CD303-expressing targets of the chimeric 122A2 antibody selected for specific glycosylation pattern.

Authors:  Nathalie Fournier; Emilie Jacque; Alexandre Fontayne; Delphine Derache; Gilles Dupont; Lucie Verhaeghe; Linda Baptista; Aurélie Dehenne; Anne-Sophie Dezetter; Aurélie Terrier; Alain Longue; Virginie Pochet-Beghin; Cecile Beghin; Sami Chtourou; Christophe de Romeuf
Journal:  MAbs       Date:  2018-04-10       Impact factor: 5.857

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.